Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474

BACKGROUND AND PURPOSE: In 2016, one person died and four others had mild‐to‐severe neurological symptoms during a phase I trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10‐2474. EXPERIMENTAL APPROACH: Pharmacodynamic and pharmacokinetic studies were performed with BIA 10‐2474, PF‐0445...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonifácio, Maria‐João, Sousa, Filipa, Aires, Cátia, Loureiro, Ana I., Fernandes‐Lopes, Carlos, Pires, Nuno M., Palma, Pedro Nuno, Moser, Paul, Soares‐da‐Silva, Patrício
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161550/
https://www.ncbi.nlm.nih.gov/pubmed/31901141
http://dx.doi.org/10.1111/bph.14973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161550/
https://www.ncbi.nlm.nih.gov/pubmed/31901141
http://dx.doi.org/10.1111/bph.14973

Ejemplares similares